Core Viewpoint - Medline Industries is planning to go public on NASDAQ with a potential valuation of $50 billion, marking it as one of the largest and most significant healthcare IPOs of the year, symbolizing a recovery in the U.S. capital markets after a prolonged downturn in the medical sector [2][6][9]. Group 1: Company Overview - Medline, founded in 1966, has evolved from a textile workshop to a leading global medical supply chain player, reporting net sales of $13.53 billion and a net profit of $655 million in the first half of 2025, reflecting a 9.7% year-over-year growth [6][10]. - The company offers a wide range of products, including surgical instruments and protective gear, serving over 125 countries, and is a key player in the North American medical supply market alongside Cardinal Health and Owens & Minor [6][10]. Group 2: IPO Significance - The IPO represents a significant exit for private equity firms Blackstone, Carlyle Group, and Hellman & Friedman, who acquired Medline for $34 billion in 2021, with potential returns exceeding 40% based on the anticipated valuation [7][10]. - Analysts view Medline's IPO as a critical indicator of investor confidence in the healthcare sector and the broader capital market, especially given the company's resilience amid cost pressures and supply chain challenges [9][16]. Group 3: Industry Implications - Medline's IPO highlights the return of value to the medical supply chain, as the company managed to achieve nearly 10% revenue growth despite ongoing cost pressures in the global healthcare system [11][12]. - The company's strategy of shifting production closer to North America and Southeast Asia aligns with U.S. efforts to enhance supply chain security, potentially increasing its market valuation due to geopolitical advantages [12][13]. - Medline's trajectory serves as a reminder for domestic companies that core competitiveness in the medical manufacturing sector lies not only in product innovation but also in systemic supply capabilities [13][14]. Group 4: Capital Market Trends - The IPO signals a shift in capital focus from high-tech innovation to the resilience of foundational manufacturing capabilities within the healthcare sector, suggesting that companies like Medline may become valuation anchors in the next phase of the market [14][16]. - The restructuring of supply chains is prompting a global rebalancing of manufacturing, presenting both challenges and opportunities for Chinese medical manufacturing firms in terms of cost, quality, and delivery capabilities [15][16]. - Medline's successful IPO could mark the beginning of a recovery in the medical capital market, encouraging other manufacturing and distribution companies to reconsider their listing strategies [16][18].

这并非 Medline 首次谋求上市。早在 2024 年底，公司就已向 SEC 保密递交过 S-1 草案 。但由于 2025 年上半年全球贸易不确定性上升，美国对中国、越南、墨西哥 等地加征关税，供应链成本短期飙升，公司出于稳健考虑推迟了发行。如今在市场环境逐渐企稳的背景下，Medline 再度重启窗口，被认为是企业经营信心与资本 市场修复的共同体现。 # 上市背后的动 因： 稳定的窗口 期 为何选择此时重启 IPO？外界普遍认为，原因主要有三方面： 其一，宏观环境趋稳。 随着美联储释放降息预期，全球融资环境较上半年显著改善。资本市场风险偏好回升，多家企业在 9 月密集重启上市计划，医疗健康作为相 对抗周期的赛道，受到机构资金的持续追捧。 其二，贸易摩擦阶段性缓和。 年初美国对多国医疗耗材与零部件加征关税，使得供应链承压。但近期关税政策出现边际放松，Medline 的跨国供应链压力有所缓 解。市场认为，这是公司敢于重新启动上市窗口的直接原因之一。 其三，医疗需求长期增长。 无论是医院端的一次性防护用品，还是家庭护理端的基础耗材，Medline 的产品线覆盖面广、刚需属性强。疫情后，医疗供应链"常态化 安全"成 ...

上海活动报名： 2025医疗器械研发创新论坛 近日，美国最大的私营医疗器械分销商Medline Industries再次推进上市进程。 多家外媒消息显示，Medline已向美国证券交易委员会（SEC）重新提交首次公开募股（IPO）招股说明书草案，更新了最新二季度财务 数据。 若上市顺利推进，公司估值有望超过500亿美元，预计筹资规模在40亿至50亿美元之间，这将成为2025年医疗器械行业规模最大的IPO， 也被视为私募股权市场和医疗健康板块的风向标。 # 贸易不 确定性 曾迫使 推迟， 如今 重启窗 口期 Medline的上市计划原定于2025年上半年推进，但彼时全球贸易局势波动明显，美国对中国、越南、墨西哥等地采购的医疗产品加征关 税，导致供应链成本上升，公司出于谨慎考虑推迟发行计划。 知情人士称，高关税和高利率叠加令私募股权基金的退出窗口延后，Medline是当时少数因宏观环境主动调整节奏的头部企业。 2021年， 黑石集团（Blackstone）、赫尔曼弗里德曼（Hellman & Friedman）、凯雷投资集团（Carlyle）联合新加坡GIC和阿布扎比主 权财富基金 ，以 约340亿美元 完成对M ...